Compare ARK Space & Defense Innovation ETF (ARKX) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Viatris Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $31.76, while Viatris Inc trades at $16.36 (market cap $18.94B). The key difference: Viatris Inc pays a 2.95% dividend while ARK Space & Defense Innovation ETF pays none, and Viatris Inc is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $17.39 |
52-Week Low | $24.97 | $8.74 |
Market Cap | — | $18.94B |
Enterprise Value | — | $31.15B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
Viatris (VTRS) trades at $16.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has beaten EPS estimates for the last three quarters, though it reported a net loss of $3.51B in 2025. Revenue has declined from $16.3B in 2022 to $14.3B in 2025. Positive news includes FDA acceptance of a new drug application for fast-acting meloxicam and a Phase 3 study success for VR-205, targeting a Japanese NDA by end of 2026.
The outlook is mixed: analyst consensus is a $20 price target with a 'Hold' bias, but high debt and negative margins pose risks. Upside potential hinges on pipeline success and debt reduction, while competitive pressures and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
